Growth hormone secretagogues
Tesamorelin
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending.
An FDA-approved GHRH analog with the strongest clinical evidence of any peptide for reducing visceral adipose tissue.
What it is
Tesamorelin is a stabilized GHRH analog approved for the reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Its trial data on visceral fat — the metabolically active fat around the organs — is the most robust in this category, and it has also been studied for cognitive endpoints.
What it's studied for
- Visceral adipose tissue reduction in randomized trials
- Triglycerides and liver-fat markers
- Cognitive performance in older adults with mild impairment
How it's used in practice
- Approved use is a specific indication; anything else is off-label and requires physician judgment
- IGF-1 and glucose are monitored during therapy
What you should know before asking about it
- Prescription medication — evaluation required, not available on request
- Can raise blood glucose and reduce insulin sensitivity in some patients
- Contraindicated in pregnancy and active malignancy
Frequently asked questions.
- What is Tesamorelin?
- Tesamorelin is a stabilized GHRH analog approved for the reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Its trial data on visceral fat — the metabolically active fat around the organs — is the most robust in this category, and it has also been studied for cognitive endpoints.
- What is Tesamorelin studied for?
- Published and ongoing research looks at visceral adipose tissue reduction in randomized trials; triglycerides and liver-fat markers; cognitive performance in older adults with mild impairment. These are areas of study, not promised outcomes.
- Is Tesamorelin FDA-approved?
- Tesamorelin is an FDA-approved prescription medication in the United States. It is prescribed only after a clinician review of your labs and history, and it is dispensed by a licensed pharmacy.
- How is Tesamorelin typically used?
- Approved use is a specific indication; anything else is off-label and requires physician judgment IGF-1 and glucose are monitored during therapy Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
- What are the risks and unknowns with Tesamorelin?
- Prescription medication — evaluation required, not available on request Can raise blood glucose and reduce insulin sensitivity in some patients Contraindicated in pregnancy and active malignancy
Sources
- 1.Published literature on Tesamorelin— PubMed, U.S. National Library of Medicine
- 2.FDA-approved prescribing information for Tesamorelin— DailyMed, U.S. National Library of Medicine
- 3.Test directory and patient service center locator— Quest Diagnostics
About this page
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.
This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.
More in Growth hormone secretagogues
Sermorelin
A growth-hormone-releasing hormone analog that prompts your own pituitary output rather than replacing it.
Ipamorelin
A selective growth-hormone secretagogue studied for GH release without meaningful cortisol or prolactin rise.
CJC-1295
A GHRH analog with extended half-life, studied to raise baseline growth-hormone and IGF-1 signaling.